ROCKVILLE, Md., Aug. 02, 2026 (GLOBE NEWSWIRE) — Ascentage Pharma Community World (NASDAQ: AAPG; HKEX: 6855), a world, industrial-stage, built-in biopharmaceutical firm engaged in the discovery, development and commercialization of new therapies to address unmet clinical needs in most cancers, this day announced the appointment of Faiçal Miyara, PhD, as Chief Enterprise Officer (CBO), accountable for the Firm’s global enterprise development, and Jim Ziegler as Chief Industrial Officer (CCO), accountable for the commercialization of the Firm’s products in the US and loads of countries outdoors of China.
Collectively, the appointments blueprint a US commercialization aim with dedicated management below Mr. Ziegler and a reinforced global enterprise development below Dr. Miyara. Each and every will express straight to Dr. Dajun Yang, Chairman and Chief Govt Officer of the Firm.
Dr. Miyara has better than Two decades of ride in oncology-centered enterprise development all the plot through leading global pharmaceutical and biotechnology companies. Ahead of joining Ascentage Pharma, he served as CBO and member of the government team at IO Biotech; prior, he served as Vice President, head of world partnering Oncology, Search and overview and Endeavor Capitals’ relationship at Ipsen. Dr. Miyara spent 5 years at Pfizer Inc., the set he co-initiated the firm’s Contemporary York-basically based Center for Therapeutic Innovation (CTI) and held senior R&D management roles, and 5 years at ImClone Programs and Eli Lilly and Firm, the set he contributed to the overview, optimization, and clinical development of FDA-accredited oncology biologics including Erbitux® (cetuximab) and Cyramza® (ramucirumab). He holds a PhD in Reproductive, Molecular, and Mobile Biology from Université Pierre et Marie Curie (Sorbonne University), France, and a Grasp’s/Engineering stage in clinical biology from the College of Medication Joseph Fourier in Grenoble, France. Reflecting his strong dedication to scientific advancement, he has authored loads of e book chapters, printed broadly in blueprint-reviewed journals, and is a lead inventor on three patents.
Mr. Ziegler is an done biopharmaceutical govt with better than 25 years of business and operational management. He has led global product P&Ls, built and scaled high-performing organizations, and brings huge commence and commercialization ride spanning a form of specialty therapies all the plot through his occupation. His ride spans commercialization technique, market get entry to, organizational development, and adverse-purposeful execution all the plot through complex oncology, hematology, and loads of specialty markets. He brings deep industrial ride from established enterprise leaders, including Amgen and Gilead Sciences, and rising biopharmaceutical companies, Iovance Biotherapeutics and Geron the set he led their global industrial teams. Earlier than coming into the biopharmaceutical enterprise, Mr. Ziegler served as an Armor Officer in the U.S. Military. He earned a B.S. from the US Protection force Academy at West Level and an M.B.A. from the University of Chicago.
Dr. Dajun Yang acknowledged: “We are cheerful to welcome Dr. Faiçal Miyara and Mr. Jim Ziegler to Ascentage Pharma’s govt management team. As loads of global registrational Segment III stories continue to come all of sudden, Ascentage Pharma, a world innovative biopharmaceutical firm dual-predominant listed on the Hong Kong Stock Change and Nasdaq, is coming into a current portion of its global expansion. The appointment of those two done executives will significantly toughen the Firm’s global enterprise development and industrial capabilities.
Dr. Miyara is an exceptionally innovative and strategically minded leader with outstanding ride in building high-payment oncology enterprise development pipelines. We are assured that his ride will further toughen and jog up the execution of our global enterprise development technique.
Mr. Ziegler brings huge ride all the plot through specialty therapeutics, including hematologic malignancies, with deep ride in product launches, market get entry to and repayment, industrial organization building, and global industrial technique. As our hematologic malignancy therapies come in the direction of global commercialization, Mr. Ziegler’s ride is highly aligned with the Firm’s global enhance technique. His management will further toughen our global industrial capabilities and jog up the enchancment of a world-class industrial organization.
Yet again, we warmly welcome Dr. Miyara and Mr. Ziegler to the Firm. We wait for working carefully with them to further toughen our management sigh in global hematologic malignancies and lift more treatment alternatives to patients worldwide.”
Dr. Faiçal Miyara acknowledged: “I am deeply honored to affix Ascentage Pharma. Ascentage Pharma is coming into a current portion of advancing its global expansion technique. I wait for working carefully with this outstanding team, leveraging my prior ride to completely improve the execution of the Firm’s global technique and the expansion of its enterprise footprint, and to reaching current heights of development along with the Firm.”
Mr. Jim Ziegler acknowledged: “I am exasperated to affix Ascentage Pharma at such a pivotal stage in its global enhance. Ascentage Pharma has built a pipeline of differentiated therapies with the likely to address important unmet needs in hematologic malignancies. I wait for working with the team to come our global industrial technique and capabilities so we can raise necessary current treatment alternatives to patients all the plot throughout the realm.”
About Ascentage Pharma
Ascentage Pharma Community World (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Firm”) is a world, industrial stage, built-in biopharmaceutical firm engaged in the discovery, development and commercialization of new, differentiated therapies to address unmet clinical needs in most cancers. The Firm has built a rich pipeline of innovative drug products and candidates that comprise inhibitors focusing on key proteins in the apoptotic pathway, equivalent to Bcl-2 and MDM2-p53, next-generation kinase inhibitors, and protein degraders.
The Firm’s first accredited product, olverembatinib, is the first new third-generation BCR-ABL1 inhibitor accredited in China for the treatment of patients with CML in chronic portion (CML-CP) with T315I mutations, CML in accelerated portion (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and 2d-generation TKIs. It’s miles roofed by the China National Reimbursement Drug Record (NRDL). Ascentage Pharma is in the indicate time conducting an FDA- and EMA-cleared registrational Segment III trial, referred to as POLARIS-2, of olverembatinib for CML, moreover to an FDA- and EMA-cleared registrational Segment III trials for patients with newly identified Ph+ ALL, referred to as POLARIS-1, and SDH-deficient GIST patients, referred to as POLARIS-3.
The Firm’s 2d accredited product, lisaftoclax, is a new Bcl-2 inhibitor for the treatment of diverse hematologic malignancies. Lisaftoclax has been accredited by China’s National Scientific Merchandise Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukemia/minute lymphocytic lymphoma (CLL/SLL) who’ve beforehand acquired a minimal of one systemic treatment including Bruton’s tyrosine kinase (BTK) inhibitors. The Firm is in the indicate time conducting four global registrational Segment III trials: the FDA- and EMA- cleared GLORA stumble on of lisaftoclax in combination with BTK inhibitors in patients with CLL/SLL beforehand handled with BTK inhibitors for better than three hundred and sixty five days with suboptimal response; the GLORA-2 stumble on in patients with newly identified CLL/SLL; the GLORA-3 stumble on in newly identified, aged and unfit patients with AML; and the FDA- and EMA-cleared GLORA-4 stumble on in patients with newly identified elevated possibility MDS.
Leveraging its important R&D capabilities, Ascentage Pharma has built a portfolio of world intellectual property rights and entered into global partnerships and loads of relationships with a form of leading biotechnology and pharmaceutical companies, equivalent to Takeda, AstraZeneca, Merck, Pfizer, and Innovent, moreover to to have a study and development relationships with leading overview institutions, equivalent to Dana-Farber Cancer Institute, Mayo Sanatorium, National Cancer Institute and the University of Michigan. For more files, consult with https://ascentage.com/
Cautionary Exhibit Concerning Forward-Searching Statements
This press release includes forward-taking a gaze statements all the plot throughout the which methodology of the Personal Securities Litigation Reform Act of 1995 and Half 27A of the Securities Act of 1933, as amended, and Half 21E of the Securities Change Act of 1934, as amended. All statements, loads of than statements of historical info, contained in this press release can be forward-taking a gaze statements, including statements that categorical Ascentage Pharma’s opinions, expectations, beliefs, plans, needs, assumptions or projections regarding future occasions or future outcomes of operations or financial situation. These forward-taking a gaze statements are subject to a different of risks and uncertainties as talked about in Ascentage Pharma’s filings with the SEC, including those space forth in the sections titled “Risk factors” and “Cautionary show camouflage regarding forward-taking a gaze statements” in its Annual Declare on Acquire 20-F for the year ended December 31, 2025, filed with the SEC on April 29, 2026, the sections headed “Forward-taking a gaze Statements” and “Risks Factors” in the prospectus of the Firm for its Hong Kong preliminary public offering dated October 16, 2019, and loads of filings with the SEC and/or The Stock Change of Hong Kong Restricted the set the Firm’s normal shares are listed it has made or it makes now and again that will space off staunch outcomes, ranges of activity, efficiency or achievements to be materially loads of from the ideas expressed or implied by these forward-taking a gaze statements. The forward-taking a gaze statements contained in this presentation attain now now not portray income forecast by the Firm’s administration.
Because these factors, you mustn’t rely on these forward-taking a gaze statements as predictions of future occasions. The forward-taking a gaze statements contained in this press release are in step with Ascentage Pharma’s current expectations and beliefs pertaining to future traits and their likely outcomes and express handiest as of the date of such statements. Ascentage Pharma does now now not undertake any responsibility to replace or revise any forward-taking a gaze statements, whether because current files, future occasions or in another case.
Contact Knowledge:
Stella Yang
Ascentage Pharma
[email protected]
+1 (301) 792-6286
